Retinoid X receptor or Retinoic acid receptor DNA-binding domain (RXR DBD or RAR DBD)

The **DNA-binding domain (DBD) of retinoid receptors**, present in both Retinoid X receptors (RXRs) and Retinoic acid receptors (RARs), is a highly conserved motif critical for specific binding to DNA response elements (such as DR1 elements) in the genome. The DBD contains two zinc finger motifs, which mediate recognition and interaction with specific DNA half-sites, thereby enabling these nuclear receptors to regulate gene expression in response to their respective ligands. The DBD is essential for dimerization (both homo- and heterodimerization), positional specificity on DNA, and combinatorial control of gene transcription through recruitment of coregulators. While crucial for receptor function, the DBD itself is not typically a direct therapeutic target, but rather forms part of the larger nuclear receptor protein that is targeted by drugs via the ligand-binding domain[1][3][4][5]. Summary: - This entry is not itself a canonical therapeutic target, but a conserved functional domain in the retinoid receptor family (not drug-targetable in isolation). - The druggable entities are the full-length Retinoid X receptor and Retinoic acid receptor, both of which contain this DNA-binding domain.

Other names

Retinoid receptor DNA-binding domainNuclear receptor DNA-binding domainRXR DBDRAR DBD

Agonists or antagonists binding to RXR or RAR ligand-binding domains induce conformational changes, promoting or inhibiting transcription of retinoic acid response elements through recruitment of transcriptional co-regulators; these ligands do not bind the DBD itself but modify its DNA interaction via structural changes in the intact receptor